Invasive Fungal Infections Market Growth Outlook: Why Analysts Expect Continued Expansion

Invasive Fungal Infections Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Invasive Fungal Infections Market Forecast: What Value Will The Market Reach By 2030?

The invasive fungal infections market has seen consistent growth in recent years. It is anticipated to expand from $7.91 billion in 2025 to $8.24 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.1%. This historical growth can be attributed to several factors including the increasing prevalence of HIV and cancer patients, the widespread use of broad-spectrum antibiotics, the established application of amphotericin B in hospitals, an increase in organ transplant procedures, and the rising incidence of hospital-acquired fungal infections.

The invasive fungal infections market size is expected to experience substantial growth in the upcoming years. It is forecast to reach $10.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This expansion during the forecast period can be attributed to factors such as the development of novel antifungal drug classes, increasing awareness of antifungal resistance, the growth of critical care infrastructure, improved diagnostic capabilities for fungal infections, and rising investment in infectious disease research. Key trends anticipated in the forecast period include the increasing incidence of invasive fungal infections in immunocompromised patients, a greater adoption of echinocandins as first-line therapy, the growing application of combination antifungal treatment strategies, the expansion of hospital-based antifungal stewardship programs, and a rising demand for broad-spectrum and targeted antifungal agents.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=97894488&type=smp&name=Invasive%20Fungal%20Infections%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Invasive Fungal Infections Market Growth Momentum: What Factors Are Shaping Demand?

The anticipated increase in the number of individuals affected by human immunodeficiency virus (HIV) is expected to propel the future growth of the invasive fungal infection market. HIV (Human Immunodeficiency Virus) infection is a virus that impairs the immune system’s ability to combat diseases and illnesses. The expanding population with weakened immune systems, particularly those with HIV (Human Immunodeficiency Virus) or AIDS (acquired immunodeficiency syndrome), face an elevated risk of invasive fungal infections, thereby opening avenues for manufacturers to create and provide specialized and more effective antifungal medications. For example, in July 2025, as reported by the Joint United Nations Programme on HIV/AIDS (UNAIDS), an international organization based in Switzerland, 40.8 million [37.0 million–45.6 million] people were living with HIV in 2024. In that same year, approximately 1.3 million [1 million–1.7 million] individuals contracted new HIV infections, and 630 000 [490 000–820 000] people died due to AIDS-related illnesses. Consequently, the rising population suffering from the human immunodeficiency virus (HIV) will be a driving force behind the expansion of the invasive fungal infection market.

Invasive Fungal Infections Market Segment Analysis: What Are The Core Market Categories?

The invasive fungal infections market covered in this report is segmented –

1) By Disease Type: Candidemia And Invasive Candidiasis, Intra Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Types

2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Types

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Candidemia And Invasive Candidiasis: Bloodstream Infections, Disseminated Candidiasis

2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis, Abscess Formation

3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis, Secondary Cryptococcal Meningitis

4) By Esophageal Candidiasis: Acute Esophageal Candidiasis, Chronic Esophageal Candidiasis

5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis, Chronic Pulmonary Histoplasmosis

6) By Other Disease Types: Aspergillosis, Mucormycosis, Other Rare Fungal Infections

Invasive Fungal Infections Market Trends Redefining Industry Growth

Major companies within the invasive fungal infection market are focusing on innovative products, such as Zisavel capsules, to boost treatment effectiveness, enhance patient results, and broaden accessibility for those impacted by serious fungal infections. Zisavel capsules, a generic antifungal medicine originating from isavuconazole, are developed to treat invasive aspergillosis and mucormycosis. These 100 mg capsules aim to present an economical option for patients, thereby increasing their reach to crucial treatment. As an illustration, in October 2023, BDR Pharmaceuticals, an India-based generic and specialty pharmaceutical company, introduced Zisavel Capsules, a generic antifungal drug, for managing invasive aspergillosis and mucormycosis. Zisavel is indicated for the treatment of invasive aspergillosis and mucormycosis, both of which are severe, potentially life-threatening fungal infections. The introduction of Zisavel is intended to make treatment more attainable for patients by considerably reducing costs compared to current alternatives like voriconazole and posaconazole.

Invasive Fungal Infections Market Top Companies Driving Competitive Growth

Major companies operating in the invasive fungal infections market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB

View The Full Invasive Fungal Infections Market Report:

https://thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Invasive Fungal Infections Market Top Region By Revenue And Market Share

North America was the largest region in the invasive fungal infections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model